If you have been reading about thymosin alpha 1 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-06-12. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Peptide | 28 amino acid residues |
| Molecular weight | Approximately 3108 Da | Depends on acetylation state |
| N-terminal modification | Acetylated | Affects charge and stability |
| Natural source | Fragment of thymosin beta-4 | Cleaved in vivo |
| Sequence length | 28 residues | Synthetic form matches natural |
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Tofu skin is produced when soy milk is boiled in an open, shallow pan, thus producing a film or skin composed primarily of a soy protein-lipid complex on the liquid surface. Tofu skin is cooked with noodles.
== Stanford Research Institute == In 1962, Finnigan and one of his coworkers, physicist and nuclear engineer P. Michael Uthe Jr., left Livermore to work for the Stanford Research Institute (SRI) in Palo Alto, California. Finnigan was hired to establish a process controls group in SRI's control systems lab. SRI did contract research projects for both business and the military. One of the projects underway at SRI, led by Kenneth R. Shoulders, was developing a quadrupole mass spectrometer. Finnigan saw the potential for using the quadrupole broadly as a detector for instrumentation and process-control, and began trying to find support for its development and commercialization.
==== Iranian people ==== Graves are free if the owner is poor. Some ancient people ancient Iranians burial colored the dead body, while others fed the body to vultures and other birds or burned the bodies. Body parts cut during the procedure were sometimes buried separately.
Sources: en.wikipedia.org
centrifuge A device used to separate substances based on size, shape, and density by centrifugation, or the rotation of vessels containing the substances around a centred axis at extremely high velocities.
Founder and Leader, The Country Playgroup. For services to Early Years Education in County Antrim. Sara Patricia Jane Walker. Volunteer, Teddington Hockey Club. For services to Hockey and Masters Hockey, and to the community in the London Borough of Richmond upon Thames. Mary Lamorna Wallis. For services to the NHS and to the community in Bloomsbury, London Borough of Camden. Penelope Jean Walters. For services to the community in Byker, Newcastle upon Tyne, particularly during Covid-19. Russell Mark Walters. Director, Cardiff Cymru and Careline Co-ordinator, Care for the Family. For voluntary service in Wales. Helen Elizabeth Walton. Policy Adviser, Rochdale Council. For services to Children in Care and Children in Poverty. Leslie John Want. For services to the community in Sketty and Swansea. Sharon Ann Warboys. For services to the community in Dunstable, Bedfordshire, particularly during Covid-19. Vivienne Ward. Lately Office Manager, Conservative Campaign Headquarters Wales and Secretary, Welsh Board of Management, Conservative Party. For Political Service. Adam Samuel Watson. Dairy Farmer, Coleraine. For services to Mental Health in the Farming Community in Northern Ireland. Hayley Marie Watson. For services to the community in Exmouth, Devon, particularly during Covid-19. The Reverend Roy Morgan Watson. For services to the community in Blaina, Blaeneau Gwent. William Joseph Watson. Director, Great North Big Band Jazz Festival. For services to Music. Timothy Edward Way. For services to the community in Westcott, Surrey. Rosemary Dale Webb.
==== Activity-based Profiling ==== To achieve functional degradomics, the enzymatic activity of proteases must be analyzed. Methods have been developed to distinguish the proteolytic activity of different enzymes in biological samples and separate active proteases from their inactive forms, namely zymogen precursors and those proteases bound by inhibitors. Two techniques are activity-based probes (ABPs) and Proteolytic Signature Peptides (PSPs). ABP molecules serve as probes to irreversibly bind only to active proteases and ignore their zymogen precursors and inhibited proteases. Placing a reactive group and a recognizable tag feature on the same molecule using a linker moiety gives an ABP molecule its structure. The reactive molecule, designed after protease inhibitor mechanisms, lends ABPs their specificity towards targeting active proteases. Once bound, the reactive group acts much like an irreversible inhibitor to the protease. Depending on the nature of the tag moiety, the ABP-protease complex can then be visualized or retrieved from biological samples for further studies of localization and quantification. Limitations including difficult production, specificity, stability, and toxicity hamper ABP development but these probes have proved useful in revealing protease biological activity and remain a promising avenue in degradomic technology. PSPs do not depend on targeting active proteases with tagged compounds but rather on quantitative proteomics using stable isotope labeled standard peptides.
Sources: en.wikipedia.org
== Scientific publications == Life Length has published to date the following articles: In addition, numerous clients of Life Length have published articles based on the results for work performed by the company demonstrating the uniqueness of the TAT® and related technologies:
== D == Dakin reaction (AKA Dakin oxidation) Dakin–West reaction Danheiser annulation Danheiser benzannulation Darapsky degradation Darzens condensation, Darzens–Claisen reaction, Glycidic ester condensation Darzens halogenation Darzens synthesis of unsaturated ketones Darzens tetralin synthesis Davis' reagent, Davis oxidation Davis–Beirut reaction De Kimpe aziridine synthesis Dehydration reaction Dehydrogenation Delépine reaction DeMayo reaction Demjanov rearrangement Demjanow desamination Dess–Martin oxidation Diazoalkane 1,3-dipolar cycloaddition Diazotisation DIBAL-H selective reduction Dieckmann condensation Dieckmann reaction Diels–Alder reaction Diels–Reese reaction Dienol–benzene rearrangement Dienone–phenol rearrangement Dimroth rearrangement Di-π-methane rearrangement Directed ortho metalation Doebner modification Doebner reaction Doebner–Miller reaction, Beyer method for quinolines Doering–LaFlamme carbon chain extension Dötz reaction Dowd–Beckwith ring expansion reaction Duff reaction Dutt–Wormall reaction Dyotropic reaction
=== Augmentation of Tumor Necrosis Factor === Injection of tuftsin intraperitoneally increases the formulation of TNF in serum and supernatants of cultured splenic and peritoneal adherent cells. This was also demonstrated in vitro using HL60 leukemia cells.
=== Legal status === Olipudase alfa was approved for medical use in Japan in March 2022. In May 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Xenpozyme, intended for the treatment of non-central nervous system (CNS) manifestations of acid sphingomyelinase deficiency type A/B or type B. Xenpozyme was reviewed under the accelerated assessment program of the European Medicines Agency (EMA). The applicant for this medicinal product is Genzyme Europe BV. Olipudase alfa was approved for medical use in the European Union in June 2022.
Sources: en.wikipedia.org
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.
It is usually described as an immunomodulatory peptide rather than a classical hormone. It does not travel to a single distant organ in the manner of an endocrine hormone. Classification varies across sources, and some texts group it with thymic peptides generally.
The broad outline involves immune cell activation, but the specific molecular steps remain under investigation. Different studies report effects on dendritic cells, T cells, and natural killer cells. No single receptor has been confirmed as the sole mediator.
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.